Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort
- 1 March 2018
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 286 (3) , 1072-1083
Abstract
In patients with hepatocellular carcinoma who were bridged to transplantation, favorable tumor biology and immune status were correlated with objective response prior to liver transplantation and, most importantly, objective response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres may enable selection of patients who are ideal candidates for liver transplantation. PurposeTo assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver transplantation, and to produce an optimized pretransplantation model for posttransplantation recurrence risk.Materials and MethodsIn this institutional review board–approved HIPAA-compliant retrospective analysis, 93 consecutive patients (73 male, 20 female; mean age, 59.6 years; age range, 23–72 years) underwent TACE with doxorubicin-eluting microspheres (DEB) (hereafter, DEB-TACE) and subsequently underwent transplantation over a 5-year period from July 7, 2011, to May 16, 2016. DEB-TACE response was based on modified Response Evaluation Criteria in Solid Tumors. Imaging responses and posttransplantation recurrence were compared with demographics, liver function, basic immune markers, treatment dose, and tumor morphology. Treatment response and recurrence were analyzed with uni- and multivariate statistics, as we...Keywords
This publication has 26 references indexed in Scilit:
- Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantationWorld Journal of Gastroenterology, 2016
- Liver transplantation for hepatocellular carcinoma: Role of inflammatory and immunological state on recurrence and prognosisWorld Journal of Gastroenterology, 2013
- Impact of tumor size, number of tumors and neutrophil‐to‐lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinomaHepatology Research, 2012
- Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient CohortRadiology, 2010
- Negative Impact of Neutrophil-Lymphocyte Ratio on Outcome After Liver Transplantation for Hepatocellular CarcinomaAnnals of Surgery, 2009
- Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantationJournal of Hepatology, 2006
- A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantationLiver Transplantation, 2005
- Platelets and Granulocytes, in Particular the Neutrophils, Form Important Compartments for Circulating Vascular Endothelial Growth FactorAngiogenesis, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002